Chronic hepatitis delta virus (HDV) infection – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Hepatitis Delta is the most severe form of viral hepatitis in humans and is caused by infection with the hepatitis delta virus (HDV). HDV is the only virus in the genus Deltaviridae. It is not classified as a viral family because it is a unique virus dependent on HBV. The HBV-dependent replication of HDV produces two forms of an RNA-binding protein known as the long and small delta antigens (Ag). All other proteins needed for the replication, especially the RNA-directed RNA polymerase activity, are provided by the host cell. Thus, it can only cause disease in individuals who carry HBV. HDV infection is majorly transmitted via the parenteral route through exposure to blood or blood products. The hepatitis delta virus expresses only one protein, the hepatitis delta antigen (HDAg), which comprises a nucleocapsid-like structure with the genome. There are two forms of HDAg: small and large. Together, these and the single-stranded RNA genome are surrounded by a lipid envelope, which is embedded with HBV-derived surface antigen (HBsAg) proteins.

 

The incidence of disease increases from the age of 40 years, reaches a peak by 50-59 years, and declines a little by the age of 70 years.

HDV was present worldwide and its local prevalence was a function of the prevalence of HBV. Approximately 5% of HBsAg carriers were estimated to be infected with HDV worldwide.

 

The competitive landscape of Chronic hepatitis delta virus (HDV) infection includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chronic hepatitis delta virus (HDV) infection across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic hepatitis delta virus (HDV) infection Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chronic hepatitis delta virus (HDV) infection – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          DNL310            Denali Therapeutics Inc. Phase 1/2

2          JR-141 JCR Pharmaceuticals Co., Ltd.  Phase 1/2

3          Idursulfase IT    Shire    Phase 1/2

4          AGT-182           ArmaGen, Inc   Phase 1

5          RGX-121          Regenxbio Inc.  Phase 1/2

6          GC1111            Green Cross Corporation           Phase 3

7          GNR-055          AO GENERIUM Phase 1

8          ABO-102          Abeona Therapeutics, Inc          Phase 1/2

9          ALDHbr Aldagen Inc.     Phase 1

10        SBC-103           Alexion Pharmaceuticals            Phase 1/2